JPRN-UMIN000014493招募中2 期
Single arm open-label trial to investigate the efficacy and safety of Lenlidomide as a treatment for recurrent or refractory Crow-Fukase (POEMS) syndrome. - Single arm open-label trial to investigate the efficacy and safety of Lenlidomide as a treatment for recurrent or refractory Crow-Fukase (POEMS) syndrome.
Chiba University Graduate School of Medicine0 个研究点目标入组 5 人开始时间: 2014年7月8日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Patients who have been administered, bortezomib, lenalidomide, melpharan within 4 weeks prior to the registration. (2) Patients who have been on steroid treatment (more than 10mg/day in predonine) within 2 weeks prior to the registration. (3) Patients who have been administered bevacizumab within 12 weeks prior to the registration. (4) Patients who could worsen acutely during the clinical trial period. (5) Patients with severe complicaitons ( cardiac failure, renal failure liver failure, bleeding enterogastric ulcer, ileus, poorly controlled diabetes. (6) Patients with malignancies. (7) Female patients who are pregnant or desire childbearing. Males who desire fertility. (8) Patients who allergic to lenalidomide or dexamethasone.
研究者
相似试验
已完成
2 期
Single arm open-label trial to investigate the efficacy and safety of FPF300 as a remmision induction treatment for POEMS (Crow-Fukase) syndromeCrow-Fukase (POEMS) syndromeJPRN-jRCT2091220135Chiba University hospital, department of neurology and clinical research center10
已完成
2 期
To evaluate the IQ enhancing effect of Swarnprashana in Preschool ChildreCTRI/2023/04/052105Shri Krishna Govt Ayurvedic College and Hospital Kurukshetra Haryana60
进行中（未招募）
1 期
A single arm trial evaluating the efficacy and safety of EVX-01 in combination with pembrolizumab in adults with unresectable or metastatic melanomaCTIS2024-512393-10-00Evaxion Biotech A/S90
进行中（未招募）
不适用
A single arm, open-label trial assessing the effect of Capecitabine (Xeloda®) on progression-free survival rate at four months in breast cancer patients with CNS progression after whole brain radiotherapy - RADEXEUCTR2008-007350-35-FRROCHE
已完成
不适用
Single arm open-label study to evaluate efficacy and safety of low intensity extracorporeal shockwave therapy in prostate cancer patients with ED after radical prostatectomyErectile dysfunctionJPRN-UMIN000022514Hiroshima University50